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A b s t r a c t 
Introduction: The most common alternative method of treatment for patients with severe mitral regurgitation (MR) is the im-
plantation of a MitraClip device.
Aim: To evaluate clinical and echocardiographic outcomes and quality of life (QoL) in patients with severe secondary MR, dis-
qualified from surgical intervention, treated by implantation of a MitraClip in comparison to conservative therapy.
Material and methods: A total of 33 patients were included. Patients were stratified by treatment method: group A, MitraClip 
implantation (n = 10); group B, conservative treatment (n = 23). Clinical, echocardiographic, and QoL (EQ-5D-3L, SF-12v2 Health 
Survey) characteristics were compared at baseline and at follow-up of 8.0 ±2.3 months.
Results: In group A, 2 deaths were observed: one patient died 7 days after MitraClip implantation, and the second patient died 
4 months after the procedure. No cases of rehospitalization were reported. In group B, 4 (17.4%) deaths and 6 (26.1%) hospital-
izations were reported. After MitraClip implantation a significant reduction of the NYHA class (p = 0.02), decrease in grade of MR 
(p = 0.01), vena contracta width (p = 0.006), effective regurgitant orifice area (EROA) (p = 0.003), regurgitant volume (p = 0.03) and 
end-diastolic left ventricle diameter (p = 0.02) as well as an improvement in QoL were reported. There were no significant changes 
in the NYHA class and QoL in the group treated conservatively. In those patients, we observed increased intercommissural mitral 
annulus diameter (p = 0.03), left atrium diameter (p = 0.002), and right ventricle dimension (p = 0.008), more severe tricuspid re-
gurgitation (p = 0.02) and lower mitral annular plane systolic excursion (p = 0.01).
Conclusions: Patients with severe secondary MR treated with the MitraClip achieved a significant reduction in symptoms and 
MR grade, as well as an improvement in QoL, as compared to patients treated conservatively.
Key words: MitraClip, heart failure, mitral regurgitation, quality of life.
S u m m a r y
In this study, we evaluated the effect of MitraClip implantation on severe functional mitral regurgitation, a procedure that 
is not fully established as beneficial for this etiology of mitral regurgitation. We revealed that percutaneous edge-to-edge 
mitral valve repair in comparison to conservative therapy improves the clinical condition of the patients, reduces mitral regur-
gitation grade and increases the quality of life. Large randomized studies are necessary to fully assess the clinical impact of 
MitraClip implantation in patients with severe functional mitral regurgitation. 
Introduction
The mitral valve is one of the most complicated me-
chanical arrangements in the human body and should be 
analyzed as a complex consisting of the annulus, leaflets, 
commissures, tendinous cords, papillary muscles, and the 
left atrial and ventricular walls [1, 2]. Damage of even 
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one part of them may significantly affect the function of 
the valve and cause mitral regurgitation (MR), which is 
one of the most prevalent valvular heart diseases. Ac-
cording to etiology, MR can be classified as primary, due 
to intrinsic valvular disease, and secondary (functional), 
without obvious structural abnormalities of the valve, 
but associated with severe left ventricle (LV) dysfunction 
especially due to coronary artery disease (ischemic MR) 
or idiopathic myocardial disease (non-ischemic MR).
In recent years we have observed the rapid develop-
ment of surgical and less invasive percutaneous mitral 
valve repair procedures. The most common alternative 
method of treatment for patients with severe MR with 
very high surgical risk or with contraindications to sur-
gical mitral valve replacement or repair is transcatheter 
edge-to-edge mitral valve repair using the MitraClip de-
vice (MitraClip, Abbott Vascular, Menlo Park, CA, USA) 
[3]. Current guidelines advise transcatheter mitral valve 
repair for severely symptomatic patients despite optimal 
medical therapy with chronic severe primary MR with fa-
vorable anatomy for this procedure and a reasonable life 
expectancy, but with prohibitive surgical risk because of 
severe comorbidities (American Guidelines – recommen-
dation IIb, B; European Guidelines – recommendation 
IIb, C) [4, 5]. In contrast, only the European Guidelines 
recommend the MitraClip procedure for patients with 
severe secondary MR (recommendation IIb, C) [4, 6], 
judging that it is associated with a  low procedural risk 
and absence of severe complications and may provide 
a  short-term improvement in functional condition and 
left ventricle function [7, 8].
Aim
Thus, our study aimed to evaluate clinical and echo-
cardiographic outcomes and quality of life (QoL) in high-
risk patients with severe secondary MR, disqualified from 
surgical intervention, treated by implantation of a Mitra-
Clip device in comparison with patients treated conser-
vatively.
Material and methods
Study population
This study was approved by the Bioethics Committee 
of the Jagiellonian University Medical College, Krakow, 
Poland (No. 122.6120.292.2015). We analyzed all pa-
tients with MR admitted to the 2nd Department of Cardi-
ology and Cardiovascular Interventions, University Hos-
pital in Krakow between January 2016 and January 2017. 
We included 33 consecutive patients (46% females) with 
severe secondary MR recognized during transthoracic 
echocardiography (TTE) according to the recommenda-
tions for the echocardiographic assessment of native 
valvular regurgitation [9]. All patients were disqualified 
from surgical mitral valve replacement or repair by a local 
heart team, because of very high surgical risk or serious 
contraindications. Patients were assigned to two groups: 
group A  (n = 10) patients who have undergone a  Mi-
traClip procedure and group B (n = 23) patients treated 
conservatively. In group A, 4 patients were treated with 
one clip, and 6 patients were treated with two clips. The 
group B subjects were patients who were waiting for 
a MitraClip procedure or with some contraindications for 
MitraClip due to anatomical reasons or patients who did 
not agree to MitraClip implantation.
The assessment of clinical, echocardiographic, and 
QoL characteristics was performed at baseline and mean 
8.0 ±2.3 months following the procedure (group A) or af-
ter inclusion in the study (group B) (8.1 ±2.4 vs. 8.0 ±2.4; 
p = 0.9). Evaluated clinical outcomes were: symptoms in 
New York Heart Association (NYHA) functional class, ma-
jor adverse cardiac events (MACE: death, stroke, myocar-
dial infarction, vascular complications, arrhythmias and 
conduction abnormalities, reoperation, thromboembolic 
complications). Additionally, the number of hospitaliza-
tions due to heart failure decompensation was assessed.
Echocardiographic assessment
All patients underwent TTE at baseline and during 
follow-up. In addition, severe MR was confirmed using 
two-dimensional and three-dimensional transesopha-
geal echocardiography (TEE) at baseline, which allowed 
better visualization of mitral valve anatomy and mecha-
nism of the valve disease. All TTE and TEE examinations 
were performed using Vivid E9 (GE Healthcare, Wauke-
sha, WI, USA). The post-processing and study evaluation 
were performed using a dedicated workstation (EchoPAC, 
GE Healthcare, Waukesha, WI, USA). All linear measure-
ments were taken using virtual calipers. The echocar-
diographic assessments of the mitral regurgitation were 
done according to the current guidelines [9, 10].
In particular, we assessed and measured: 
–  severity of MR: vena contracta width (in case multiple 
jets – vena contracta of dominant jet), regurgitant vol-
ume, effective regurgitant orifice area (EROA),
–  morphometric mitral valve parameters: systolic tenting 
area, systolic tenting height. Mitral annulus diameters: 
aorto-mural, annulus/anterior leaflet ratio in paraster-
nal long-axis TTE view and intercommissural diameter 
in the modified apical two-chamber view, 
–  left ventricle (LV) geometry and functions: end-diastolic 
and end-systolic LV diameters in parasternal long-axis, 
LV sphericity index in apical four-chamber view, major 
LV dimension in three-chamber view, LV ejection frac-
tion, dp/dt (calculated from the MR Doppler trace), mi-
tral annular plane systolic excursion,
–  atrial parameters: left atrium diameter in parasternal 
long axis, left atrium indexed volume, right atrium area 
and indexed volume,
–  other parameters associated with the right heart: right 
ventricle linear dimension (maximal transversal dimen-
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sion in the basal one third of right ventricle inflow at 
end-diastole), systolic pulmonary artery pressure, tri-
cuspid annular plane systolic excursion.
Quality of life assessment
The QoL was assessed personally with the self-re-
ported Polish validated version of the EQ-5D-3L ques-
tionnaire and SF-12v2 Health Survey (SF-12v2). The EQ-
5D-3L is a standardized instrument for measurement of 
health-related QoL, consisting of a  descriptive system 
and the Visual Analog Scale. Respondents can score each 
domain representing various aspects of health: mobility, 
self-care, usual activities, pain/discomfort and anxiety/
depression, from one (no problems) to three (extreme 
problems) points [11, 12]. The SF-12v2 is a multipurpose, 
short-form health survey with 12 questions that brings 
an eight-scale profile of functional health together with 
well-being, the preference-based Health Utility Index and 
two psychometrically based components: Physical and 
Mental Health Composite Summary (PCS, MCS) [13].
Statistical analysis 
Quantitative variables were described using means 
and standard deviations. Categorical variables were pre-
sented as percentages. The Shapiro-Wilk test was used to 
determine whether the quantitative data were normally 
distributed. Direct comparison between groups was con-
ducted using Student’s t-test and the Mann-Whitney 
U  test. The Wilcoxon signed-rank test (for non-normal 
distribution of data) or paired Student’s t-test (for nor-
mally distributed data) was applied for assessment of 
changes in particular dimensions of a questionnaire as-
sessing QoL and echocardiographic parameters. We per-
formed statistical analyses with Statistica v13 (StatSoft 
Inc., Tulsa, OK, USA). A p-value of < 0.05 was considered 
to be statistically significant.
Results
Baseline
The mean age of the 33 included patients was 72.6 
±10.4 years. The average body mass index was 27.9 
±4.5 kg/m2 and mean body surface area was 1.9 ±0.2 m². 
Baseline clinical characteristics of patients are shown in 
Table I. Patients from group A have a lower rate of pre-
vious coronary artery bypass grafting but a higher rate 
of cardiac resynchronization therapy, as compared to pa-
tients in group B (p < 0.05). No other differences in base-
line characteristics were noted between groups. Mitral 
regurgitation in all cases was caused by restricted leaflet 
motion in systole (Carpentier IIIb). Additionally, in 21 cas-
es (63.6%) (7 patients from group A (70.0%) and 14 from 
group B (60.9%)) annular dilatation (Carpentier I) coex-
isted with restricted leaflet motion. At baseline echocar-
diography, groups differed only in LV sphericity index and 
mitral annular plane systolic excursion (p < 0.05), while no 
other differences were found (Table II). Baseline param-
eters of QoL assessed using EQ-5D-3L and SF12v2 ques-
tionnaires were comparable between groups (Table III, 
Figure 1).
Follow-up
In group A after implantation of the MitraClip device, 
1 patient had a  stroke 7 days after the procedure and 
died (1 patient, 10.0%). Other periprocedural MACE were 
not reported. Four months after the procedure, another 
patient (10.0%) died due to severe heart failure decom-
pensation (other circumstances of death are unknown). 
Remaining patients from this group had no hospitaliza-
tions for cardiac reasons during follow-up. After Mitra-
Clip implantation a significant reduction in heart failure 
symptoms on the NYHA scale was observed (p = 0.02). 
A  decrease in grade of MR (p = 0.01), vena contracta 
width (p = 0.006), EROA (p = 0.003), regurgitant volume 
(p = 0.03), and end-diastolic LV diameter (p = 0.02), as 
well as an increase in mean transvalvular mitral gradient 
(p = 0.03), was observed in patients after MitraClip im-
plantation (Table II).
In group B we noted 4 (17.4%) deaths at a mean of 
5.0 ±2.8 months after enrollment. The causes of death 
were: severe heart failure decompensation, complicated 
by pulmonary edema (3 patients, 13.0%) and infection 
(1 patient, 4.3%). Furthermore, a  substantial number of 
hospitalizations caused by heart failure decompensation 
(4 patients, 17.4%), chest pain (1 patient, 4.3%), and deep 
vein thrombosis (1 patient, 4.3%) were noted in group B. 
No reduction in heart failure symptoms was observed in 
patients treated conservatively (p = 0.4). In those patients, 
we observed an increased intercommissural mitral annulus 
diameter (p = 0.03), left atrium diameter (p = 0.002), right 
ventricle dimension (p = 0.008) and more severe tricuspid 
regurgitation (p = 0.02) together with lower mitral annular 
plane systolic excursion (p = 0.01) in TTE examination per-
formed at follow-up in comparison with baseline (Table II). 
At follow-up significantly lower MR (p < 0.001), vena 
contracta width (p < 0.001), EROA (p = 0.003), regurgitant 
volume (p = 0.007), right ventricle dimension (p = 0.02), 
and mean transvalvular mitral gradient (p = 0.01) were 
observed in group A as compared to group B (Table II).
Improvement in QoL after the intervention was con-
firmed in group A patients in the following domains of 
the SF12v2 questionnaire: Physical Functioning (32.5 
±6.6 vs. 41.3 ±5.9; p = 0.03), Role-Physical (34.2 ±6.0 vs. 
40.5 ±6.4; p = 0.04), Role-Emotional (25.1 ±0.1 vs. 35.5 
±9.6; p = 0.04) and Physical Component Summary (34.7 
±6.2 vs. 42.6 ±5.6; p = 0.04). Additionally, the Health Util-
ity Index in this group was significantly higher after the 
observation period (0.6 ±0.1 vs. 0.7 ±0.1; p = 0.04) (Fig-
ure 1). We did not observe significant changes in results 
of the EQ-5D-3L questionnaire in group A (Table III). 
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In group B, the results of the EQ-5D-3L, as well as the 
SF12v2, were comparable at both time points. No differ-
ences in changes of the EQ-5D-3L Visual Analogue Scale 
from baseline to follow-up were found in both groups 
(Table III).
At follow-up, in a direct comparison between groups, 
differences in parameters of QoL were noted in terms 
of self-care EQ-5D-3L (p = 0.007), where all patients in 
group A  reported “no problem” (Table III). Furthermore, 
higher scores were obtained in group A in comparison to 
group B in the Physical Functioning domain (41.3 ±5.9 vs. 
33.5 ±5.4; p = 0.007) and Physical Component Summary 
(42.6 ±5.6 vs. 37.0 ±4.3; p = 0.01) of SF12v2 (Figure 1).
Discussion
Our study shows that percutaneous edge-to-edge 
mitral valve repair improves the clinical condition of the 
patients, expressed as a reduction in heart failure symp-
toms. However, we observed two deaths in patients with 
an implanted MitraClip device (20.0%). On the other 
hand, there were no hospitalizations caused by heart 
failure decompensation in remaining patients after Mi-
traClip implantation, while, in contrast, these were re-
ported in 17.4% of patients from group B. 
In this study, we analyzed only symptomatic patients 
with severe secondary MR and severely depressed sys-
tolic LV function, disqualified from surgical treatment. 
Patients with heart failure with reduced ejection fraction 
and severe MR, with comorbidities or very high surgical 
risk, may be qualified for the MitraClip procedure. In 
clinical daily practice access to this new intervention is 
still very limited. Other methods of invasive treatment 
for such patients are not available. A  meta-analysis by 
Chiarito et al. compared patients with functional and de-
Table I. Baseline clinical characteristics of patients
Parameter Group A (n = 10) Group B (n = 23) P-value
Age (mean ±SD) [years] 71.8 ±7.8 73.0 ±11.5 0.43
Coronary artery disease confirmed in angiography (%) 100.0 87.0 0.25
Previous myocardial infarction (%) 70.0 78.3 0.63
Previous percutaneous coronary intervention (%) 70.0 60.9 0.64
Previous coronary artery bypass grafting (%) 0.0 34.8 0.04*
Cardiac resynchronization therapy (%) 70.0 26.1 0.02*
Arterial hypertension (%) 80.0 87.0 0.64
Diabetes mellitus type II (%) 30.0 26.1 0.84
Atrial fibrillation (%) 60.0 60.9 0.98
Hyperlipidemia (%) 70.0 65.2 0.81
Ever-smoker (%) 20.0 52.2 0.10
Chronic kidney disease (%) 20.0 52.2 0.10
Chronic obstructive pulmonary disease (%) 30.0 8.7 0.13
Thyroid disease (%) 10.0 26.1 0.32
Previous stroke/transient ischemic attack (%) 30.0 13.0 0.27
NT-proBNP (mean ± SD) [pg/ml] 3132.3 ±2374.6 3083.1 ±2913.1 0.72
Body mass index (mean ± SD) [kg/m2] 29.4 ±3.7 27.3 ±4.7 0.15
Body surface area (mean ± SD) [m2] 1.9 ±0.1 1.9 ±0.2 0.32
EuroSCORE II (mean ± SD) (%) 3.9 ±1.7 6.2 ±3.8 0.12
New York Heart Association (NYHA) class (%):
I 0.0 0.0 0.96
II 10.0 8.7
III 70.0 73.9
IV 20.0 17.4
N – number of samples, SD – standard deviation, *statistically significant. 
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Table II. Results of obtained echocardiographic data (mean ± standard deviation) at baseline and during follow-
-up in groups A and B. Results do not include patients who died during the follow-up period (group A: n = 8, 
group B: n = 19)
Parameter Group A Group B Group 
A vs. B 
at baseline
Group 
A vs. B at 
follow-upBaseline Follow-up P-value Baseline Follow-up P-value
Mitral regurgitation, n (%):
Mild 0 2 (25.0) 0.01* 0 0 > 0.05 1.0 < 0.001*
Mild/moderate 0 2 (25.0) 0 0
Moderate 0 4 (50.0) 0 1 (5.3)
Severe 8 (100) 0 19 (100.0) 18 (94.7)
Vena contracta width [mm] 6.6 ±0.9 3.3 ±1.4 0.006* 7.2 ±1.2 7.6 ±1.3 0.1 0.4 < 0.001*
Regurgitant volume [ml] 37.6 ±13.8 19.8 ±6.6 0.03* 38.4 ±9.4 39.5 ±13.0 0.8 0.9 0.007*
Effective regurgitant orifice  
area [mm2]
25.1 ±7.7 13.0 ±5.3 0.003* 26.1 ±7.3 27.2 ±8.7 0.3 0.8 0.003*
Systolic tenting area [cm2] 3.5 ±0.6 – – 3.5 ±1.1 3.5 ±1.4 0.7 0.9 –
Systolic tenting height [mm] 6.6 ±2.3 – – 8.8 ±2.6 9.4 ±3.2 0.4 0.08 –
Intercommissural mitral annulus 
diameter [mm]
40.0 ±6.9 39.0 ±6.2 0.3 38.7 ±6.7 40.5 ±5.9 0.03* 1.0 0.7
Aorto-mural mitral annulus 
diameter [mm]
42.3 ±2.5 40.7 ±1.2 0.2 39.7 ±5.7 39.7 ±5.7 1.0 0.5 1.0
Aorto-mural mitral annulus/
anterior leaflet ratio
1.98 ±0.07 1.91 ±0.09 0.2 1.97 ±0.4 1.98 ±0.5 0.8 0.95 0.9
End-diastolic LV diameter [mm] 70.8 ±7.8 67.0 ±8.0 0.02* 65.6 ±12.0 67.0 ±11.4 0.09 0.7 0.97
End-systolic LV diameter [mm] 61.6 ±9.1 59.8 ±11.1 0.4 57.2 ±10.7 55.8 ±13.7 0.5 0.3 0.5
LV sphericity index 1.3 ±0.1 1.4 ±0.02 0.7 1.5 ±0.2 1.5 ±0.2 1.0 0.04* 0.2
Major dimension of LV in  
three-chamber view [mm]
90.3 ±18.1 92.0 ±15.9 0.8 87.0 ±11.6 87.6 ±10.4 0.9 0.7 0.6
LV ejection fraction (%) 26.1 ±9.4 25.4 ±8.5 0.7 31.8 ±10.9 31.6 ±13.2 0.9 0.18 0.2
dp/dt max 687.1 ±178.8 782.0 ±248.7 0.2 888.6 ±343.6 836.4 ±194.3 0.6 0.4 0.7
LA diameter [cm] 54.3 ±6.2 52.1 ±4.8 0.29 55.6 ±8.2 60.5 ±10.5 0.002* 0.7 0.05
LA indexed volume [ml/m2] 80.7 ±23.5 60.5 ±30.8 0.3 84.4 ±34.7 97.6 ±43.8 0.08 0.7 0.1
RA area [cm2] 24.8 ±7.6 22.9 ±5.3 0.5 28.2 ±7.3 29.8 ±7.8 0.2 0.4 0.09
RA indexed volume [ml/m2] 45.1 ±14.8 37.6 ±14.9 0.6 55.5 ±25.8 65.6 ±25.5 0.2 0.5 0.1
RV dimension [cm] 41.8 ±6.6 38.3 ±6.9 0.3 43.8 ±5.8 47.7 ±6.1 0.008* 0.96 0.02*
Systolic pulmonary artery 
pressure [mm Hg]
62.0 ±18.3 53.4 ±18.3 0.4 56.4 ±17.5 59.8 ±20.1 0.6 0.5 0.5
TAPSE [mm] 14.0 ±2.9 17.7 ±5.9 0.1 15.8 ±3.0 14.8 ±2.9 0.3 0.2 0.2
MAPSE [mm] 9.3 ±1.7 10.7 ±3.2 0.2 12.2 ±1.9 10.1 ±2.2 0.01* 0.02* 0.8
Mean transvalvular mitral 
gradient [mm Hg]
2.2 ±1.0 4.7 ±0.8 0.03* 2.4 ±1.3 2.7 ±1.3 0.05 0.8 0.01*
Tricuspid regurgitation: 
Mild 3 (37.5%) 6 0.4 10 (52.6%) 5 (26.3%) 0.02* 0.76 0.08
Moderate 5 (62.5%) 1 5 (26.3%) 9 (47.4%)
Severe 0 1 4 (21.1%) 5 (26.3%)
N – number of samples, LV – left ventricle, RV – right ventricle, LA – left atrium, RA – right atrium, MAPSE – mitral annular plane systolic excursion, TAPSE – tricuspid 
annular plane systolic excursion, *statistically significant.
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Table III. Results of EQ-5D-3L questionnaire (n, %) at baseline and during follow-up in groups A and B. Results 
do not include patients who died during the observation period (group A: n = 8, group B: n = 19)
Variable Group A Group B Group A  
vs. B at 
baseline
Group A  
vs. B at 
follow-upBaseline Follow-up P-value Baseline Follow-up P-value
Mobility, EQ-5D-3L:
No problem 0 1 (12.5%) 0.2 0 2 (10.5%) 0.2 0.2 0.7
Some problems 6 (75.0%) 7 (87.5%) 18 (94.7%) 16 (84.2%)
Extreme problems 2 (25.0%) 0 1 (5.3%) 1 (5.3%)
Self-Care, EQ-5D-3L:
No problem 4 (50.0%) 8 (100.0%) 0.07 5 (26.3%) 8 (42.1%) 0.1 0.2 0.007*
Some problems 4 (50.0%) 0 13 (68.4%) 11 (57.9%)
Extreme problems 0 0 1 (5.3%) 0
Usual Activities, EQ-5D-3L:
No problem 2 (25.0%) 4 (50.0%) 0.07 2 (10.5%) 5 (26.3%) 0.1 0.7 0.2
Some problems 4 (50.0%) 4 (50.0%) 13 (68.4%) 11 (57.9%)
Extreme problems 2 (25.0%) 0 4 (21.1%) 3 (15.8%)
Pain/Discomfort, EQ-5D-3L:
No problem 3 (37.5%) 5 (62.5%) 0.2 6 (31.6%) 6 (31.6%) 0.7 0.7 0.2
Some problems 5 (62.5%) 3 (37.5%) 12 (63.2%) 13 (68.4%)
Extreme problems 0 0 1 (5.3%) 0
Anxiety/Depression, EQ-5D-3L:
No problem 3 (37.5%) 4 (50.0%) 0.6 4 (21.1%) 9 (47.4%) 0.2 0.4 0.8
Some problems 5 (62.5%) 4 (50.0%) 15 (78.9%) 9 (47.4%)
Extreme problems 0 0 0 1 (5.3%)
EQ Visual Analogue Scale  
(mean ± standard deviation) 
39.4 ±14.5 48.1 ±23.0 0.2 39.2 ±13.9 40.8 ±12.8 0.7 0.98 0.3
generative MR treated by percutaneous edge-to-edge re-
pair and concluded that this method is an efficacious and 
safe option in patients with both types of mitral valve 
disease [14]. A few more studies reported better surviv-
al after transcatheter mitral valve repair compared with 
conservative treatment in patients with LV dysfunction 
and secondary MR [15, 16]. However, the authors em-
phasized that large, randomized studies are necessary to 
fully assess the clinical impact of the procedure in these 
two different MR etiologies.
Our results are convergent with other studies, which 
also showed an improvement in the severity of MR as-
sessed by echocardiography in patients with an implant-
ed MitraClip device compared with baseline [17–21]. In 
addition, MitraClip implantation induces significant re-
verse remodeling of LV, which is substantial in advanced 
systolic heart failure and bring clinical benefits for these 
patients [15, 22]. In our study, we also observed a reduc-
tion of end-diastolic LV diameter after the intervention, 
but other LV parameters remained unchanged at fol-
low-up. 
Possible mechanisms by which ischemia can cause 
mitral regurgitation include asymmetric annular dilata-
tion. Percutaneous mitral valve repair with the MitraClip 
has proved to reduce the size and area of the mitral valve 
annulus [23]. Our baseline and follow-up mitral annu-
lus diameters and annulus/anterior leaflet ratio values 
confirmed annular dilatation associated with MR. In the 
group treated conservatively intercommissural mitral 
annulus diameter increased during the follow-up period, 
which was not observed in the group with the MitraClip.
The QoL assessment is an essential component in 
evaluating the efficacy of all the benefits obtained after 
the procedure. Previous studies showed that the Mitra-
Clip provides improvements in physical capacity, physical 
and mental functioning and disease-specific QoL in the 
majority of patients, but huge between-study heteroge-
neity was observed between individual studies [24]. The 
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SF12v2 determines whether the scores for the PCS, MCS 
and particular health domain scales deviate from what 
is considered the average range for the U.S. general pop-
ulation [13]. Mean pre-procedural scores of our patients 
showed severe impairment of perceived QoL, not only in 
PCS and MCS scores but also in particular evaluated ar-
eas. It is important to note that QoL improvement is ob-
served only in patients with interventional therapy and 
mainly focuses on PCS (Figure 1).
Limitations
The main limitation of this study is the relatively small 
sample size that is associated with the limited number of 
MitraClip procedures performed in our center. No details 
about the technique of MitraClip implantation were col-
lected. On the other hand, the sample size was too small to 
assess any relationship between implantation technique 
and achieved outcomes. Other limitations are related to 
the single-center registry nature of this study. Moreover, 
non-disease-specific instruments for QoL assessments 
were used. However, we believe that these limitations do 
not impede our analysis and presented results.
Conclusions
Patients with severe secondary MR treated with 
the MitraClip system achieved a  significant reduction 
of symptoms, MR grade and end-diastolic LV diameter 
during follow-up. In contrast, patients who remained 
on conservative therapy showed a  higher incidence of 
hospitalization for heart failure, and increased intercom-
missural mitral annulus diameter, left atrium diameter, 
and right ventricle dimension, as well as more severe tri-
cuspid regurgitation. Furthermore, a significant improve-
ment in the QoL assessed by SF12v2 was observed after 
percutaneous edge-to-edge repair in comparison to con-
servative therapy.
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